• Philadelphia, PA (October 12, 2020) – Oncoceutics, Inc. announced that the European Patent Office has issued a Decision to Grant for a Composition of Matter patent for ONC212, one of the company’s next-generation oncology drug candidates. The company also announced that a pending ONC201 patent has been granted for Mexico and that it received a Certificate of Grant for a Composition of Matter patent for ONC201 in Japan.

    These new patents, combined with a number of patents issued since the beginning of 2020, including, among others, patents for Composition of Matter for ONC201 in China and for ONC206 in Australia and Japan, provide the company with a comprehensive global patent portfolio for its lead compound ONC201, currently in a pivotal program for H3 K27M-mutant glioma and for its next generation compounds ONC206 and ONC212.

    “Patent offices across the globe have recognized the novelty of our imipridone platform and have granted us a large number of Composition of Matter, use, and process patents,” said Martin Stogniew, Ph.D., Chief Development Officer at Oncoceutics. “We are pleased that our patents for ONC201 and our next generation compounds provide the company with more than 15 years of patent protection in all major pharmaceutical markets, with up to 5 additional years of regulatory exclusivity extensions in certain markets.”

    About Oncoceutics

    Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds called imipridones that selectively target G protein-coupled receptors for oncology. ONC201 is an orally active small molecule DRD2 antagonist and ClpP agonist in late-stage clinical development for H3 K27M-mutant glioma with additional indications under clinical investigation. ONC206 is the second clinical-stage imipridone that is under investigation for central nervous system tumors. The company is supported by grants from NCI, FDA, The Musella Foundation, Michael Mosier Defeat DIPG Foundation, Dragon Master Foundation, The ChadTough Foundation, the National Brain Tumor Society, and a series of private and public partnerships.

    Visit Oncoceutics or contact press@oncoceutics.com for more information.

Photostream